|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Risk factors of prognosis after acute kidney injury in hospitalized patients显示文摘 | Sasa Nie Zhe Feng Lihua Xia Jiuxu Bai Fenglin Xiao Jian Liu Li Tang Xiangmei Chen | 2017 | Frontiers of Medicine2017，11，3： | 7 |
| 2 | Motion rule of electronically pattern system on a high speed warp knitting machine 显示文摘 | XIA Fenglin GE Mingqiao | 2009 | Fibers & Textiles in Eastern Europe2009，17，4： | 1 |
| 3 | Contribution of beef base to aroma characteristics of beeflike process flavour assessed by descriptive sensory analysis and gas chromatography olfactometry and partial least squares regression显示文摘 | Shiqing Song Xiaoming Zhang Khizar Hayat Meigui Huang Ping Liu Eric Karangwa Fenglin Gu Chengsheng Jia Shuqin Xia Zuobing Xiao Yunwei Niu | 2010 | Journal of Chromatography A2010，，49： | 1 |
| 4 | Motion rule of electronically pattern system on a high speed warp knitting machine显示文摘 | Xia Fenglin Ge Mingqiao | 2009 | Fibers & Textilesin Eastern Europe2009，17，4： | 1 |
| 5 | Comparison between structures and properties of ABS nanocomposites derived from two different kinds of OMT 显示文摘 | CAI Yibing HUANG Fenglin XIA Xin | 2010 | J Mater Eng Perform2010，19，2： | 1 |
| 6 | Motion rule of electronically pattern system on a high speed warp knitting machine显示文摘 | XIA Fenglin GE Mingqiao | | 0，，04： | 1 |
| 7 | Characteristics and antioxidant activity of ultrafiltrated Maillard reaction products from a casein–glucose model system显示文摘 | Fenglin Gu Jin Moon Kim Khizar Hayat Shuqin Xia Biao Feng Xiaoming Zhang | 2009 | Food Chemistry2009，，1： | 1 |
| 8 | Motion rule of electronically pattern system on a high speed warp knitting machine 显示文摘 | XIA Fenglin GE Mingqiao | 2009 | Fibers & Textiles in Eastern Europe2009，17，4： | 1 |
| 9 | ACSL5,a prognostic factor in acute myeloid leukemia,modulates the activity of Wnt/β-catenin signaling by palmitoylation modification显示文摘Acyl-CoA synthetase long chain family member 5(ACSL5),is a member of the acyl-CoA synthetases(ACSs)family that activates long chain fatty acids by catalyzing the synthesis of fatty acyl-CoAs.The dysregulation of ACSL5 has been reported in some cancers,such as glioma and colon cancers.However,little is known about the role of ACSL5 in acute myeloid leukemia(AML).We found that the expression of ACSL5 was higher in bone marrow cells from AML patients compared with that from healthy donors.ACSL5 level could serve as an independent prognostic predictor of the overall survival of AML patients.In AML cells,the ACSL5 knockdown inhibited cell growth both in vitro and in vivo.Mechanistically,the knockdown of ACSL5 suppressed the activation of the Wnt/β-catenin pathway by suppressing the palmitoylation modification of Wnt3a.Additionally,triacsin c,a pan-ACS family inhibitor,inhibited cell growth and robustly induced cell apoptosis when combined with ABT-199,the FDA approved BCL-2 inhibitor for AML therapy.Our results indicate that ACSL5 is a potential prognosis marker for AML and a promising pharmacological target for the treatment of molecularly stratified AML. | Wenle Ye Jinghan Wang Jiansong Huang Xiao He Zhixin Ma Xia Li Xin Huang Fenglin Li Shujuan Huang Jiajia Pan Jingrui Jin Qing Ling Yungui Wang Yongping Yu Jie Sun Jie Jin | 2023 | Frontiers of Medicine2023，17，4： | 0 |
| 10 | Development Strategy and Countermeasures of China's CBM Industry under the Goal of “Carbon Peak and Neutrality”显示文摘China’s coalbed methane(CBM) industry is in an extremely important “climbing period” and “strategic opportunity period”,which can be generally characterized by “three low and one small”:low degree of exploration and development,low adaptability of main technology,low return on investment and small development scale.Under the “carbon peak and neutrality” background,the development status of CBM industry is systematically combed.The resources,technology,management problems and reasons are analyzed.Strategies and countermeasures to accelerate the industrial development are put forward according to the factors such as efficient development of resources,major technical breakthrough,talent team training,policy formulation and implementation,return on investment and so on.The existing problems are as follows:(a) The overall occurrence conditions in China are complicated and the development is difficult compared with the other countries.(b) The research precision accuracy of CBM resource conditions is not enough.(c) The adaptability of technology is poor.(d) The management mode is not suitable.In view of these problems,this paper puts forward the “two steps” development strategy and the technical and management countermeasures of “five in one”.The corresponding “five in one” technology and management countermeasures are the formulation and implementation of relevant safeguard measures in accordance with the principle of collaborative innovation in five aspects:resources,technology,talents,policies and investment.Through the above measures,the dream and grand blueprint of CBM industry shall be realized. | Fengyin Xu Xia Yan Fenglin Wang Xinyuan Ma Jian Yun Hongna Wang Borui Xu Shuangyuan Zhang Delei Mao | 2023 | Journal of Earth Science2023，34，4： | 0 |
| 11 | Abivertinib inhibits megakaryocyte differentiation and platelet biogenesis显示文摘Abivertinib,a third-generation tyrosine kinase inhibitor,is originally designed to target epidermal growth factor receptor(EGFR)-activating mutations.Previous studies have shown that abivertinib has promising antitumor activity and a well-tolerated safety profile in patients with non-small-cell lung cancer.However,abivertinib also exhibited high inhibitory activity against Bruton’s tyrosine kinase and Janus kinase 3.Given that these kinases play some roles in the progression of megakaryopoiesis,we speculate that abivertinib can affect megakaryocyte(MK)differentiation and platelet biogenesis.We treated cord blood CD34+hematopoietic stem cells,Meg-01 cells,and C57BL/6 mice with abivertinib and observed megakaryopoiesis to determine the biological effect of abivertinib on MK differentiation and platelet biogenesis.Our in vitro results showed that abivertinib impaired the CFU-MK formation,proliferation of CD34+HSC-derived MK progenitor cells,and differentiation and functions of MKs and inhibited Meg-01-derived MK differentiation.These results suggested that megakaryopoiesis was inhibited by abivertinib.We also demonstrated in vivo that abivertinib decreased the number of MKs in bone marrow and platelet counts in mice,which suggested that thrombopoiesis was also inhibited.Thus,these preclinical data collectively suggested that abivertinib could inhibit MK differentiation and platelet biogenesis and might be an agent for thrombocythemia. | Jiansong Huang Xin Huang Yang Li Xia Li Jinghan Wang Fenglin Li Xiao Yan Huanping Wang Yungui Wang Xiangjie Lin Jifang Tu Daqiang He Wenle Ye Min Yang Jie Jin | 2022 | Frontiers of Medicine2022，16，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员